Teams at the University of Pittsburgh and UPMC reported results from a first-in-human approach that trains the immune system to accept donor livers. The program uses donor-specific immune tolerance strategies, aiming to reduce reliance on lifelong immunosuppression by shifting how rejection risk is controlled after transplantation. The work is positioned as a clinical step toward operational tolerance—where immune acceptance is induced rather than continuously suppressed—following decades of transplant immunology advances. Researchers presented the trial concept as a potential platform that could alter how clinicians think about post-transplant long-term management. For transplant-focused biotech and clinical programs, the trial highlights an area of renewed investment: regulatory-compatible immune modulation that can lower toxicity and improve quality of life for recipients.